Shares of Lantheus Holdings Inc. (NASDAQ:LNTH) shot up 7.4% during mid-day trading on Friday . The company traded as high as $6.10 and last traded at $6.10, with a volume of 127,073 shares trading hands. The stock had previously closed at $5.68.

A number of research firms have recently issued reports on LNTH. Zacks Investment Research upgraded Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $7.00 price objective on the stock in a research report on Monday. Jefferies Group restated a “buy” rating on shares of Lantheus Holdings in a research report on Friday, August 5th. Finally, Credit Suisse Group AG set a $4.00 price objective on Lantheus Holdings and gave the company a “hold” rating in a research report on Friday, August 5th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Lantheus Holdings currently has an average rating of “Buy” and an average price target of $5.80.

The company has a market cap of $195.69 million and a price-to-earnings ratio of 7.27. The company’s 50 day moving average is $4.39 and its 200 day moving average is $2.70.

Lantheus Holdings (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, August 4th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.18. The business earned $78 million during the quarter, compared to analyst estimates of $72.66 million. On average, equities research analysts forecast that Lantheus Holdings Inc. will post $0.48 earnings per share for the current year.

Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.